1. Home
  2. TXG vs KYMR Comparison

TXG vs KYMR Comparison

Compare TXG & KYMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo 10x Genomics Inc.

TXG

10x Genomics Inc.

SELL

Current Price

$81.69

Market Cap

9.3B

Sector

Industrials

ML Signal

SELL

Logo Kymera Therapeutics Inc.

KYMR

Kymera Therapeutics Inc.

HOLD

Current Price

$122.50

Market Cap

9.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TXG
KYMR
Founded
2012
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Laboratory Analytical Instruments
Medicinal Chemicals and Botanical Products
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.3B
9.0B
IPO Year
2019
2020

Fundamental Metrics

Financial Performance
Metric
TXG
KYMR
Price
$81.69
$122.50
Analyst Decision
Buy
Strong Buy
Analyst Count
18
24
Target Price
$77.50
★ $139.83
AVG Volume (30 Days)
★ 3.7M
762.4K
Earning Date
11-05-2026
10-29-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 76.97
N/A
EPS
★ N/A
N/A
Revenue
★ $245,893,000.00
$39,211,000.00
Revenue This Year
N/A
$167.19
Revenue Next Year
$10.11
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 68.06
N/A
52 Week Low
$12.44
$55.66
52 Week High
$102.81
$130.05

Technical Indicators

Market Signals
Indicator
TXG
KYMR
Relative Strength Index (RSI) 56.91 64.47
Support Level $74.60 $110.64
Resistance Level $102.81 $128.95
Average True Range (ATR) 6.01 5.16
MACD 0.47 1.72
Stochastic Oscillator 70.45 76.12

Price Performance

Historical Comparison
TXG
KYMR

About TXG 10x Genomics Inc.

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives operates from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).

About KYMR Kymera Therapeutics Inc.

Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.

Share on Social Networks: